CRSP
CRISPR Therapeutics AG
NASDAQ · Healthcare · Biotechnology · CH
$55.79
−1.24%Next report
Analyst consensus
- Next report date
- Nov 9, 2026
- EPS estimate
- -$1.06
- Revenue estimate
- $14.8M
Latest reported
- Last report date
- Aug 3, 2026
- EPS actual
- -$0.94
- EPS estimate
- -$1.19
- Revenue actual
- $10.2M
- Revenue estimate
- $7.4M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +416.7%
- Revenue beats (12Q)
- 6
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $83
- PT range
- $80 – $88
- Analysts
- 4
4 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 9, 2026